TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen

Core Insights - TREMFYA® provides the option for self-administration from the beginning of treatment, enhancing patient convenience and adherence [1] - The drug demonstrated significant clinical remission and endoscopic improvement rates compared to placebo at Week 12 with a subcutaneous induction regimen, aligning with intravenous induction results [1] - Johnson & Johnson is launching a head-to-head study to establish the superiority of TREMFYA® over Skyrizi® (risankizumab) in treating Crohn's disease, reflecting confidence in its clinical profile [1]